ArticleMolecular neurobiology2025
Neuroprotective and Antidepressant Effects of Isorhamnetin: Mechanistic Evaluations in a Reserpine-Induced Mouse Model of Pain and Depression.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic potential of CMPP, a novel maleimide derivative, in a reserpine-induced mouse model of pain-depression dyad.Biochemistry and biophysics reports · 2026Article
- Network Pharmacology and Experimental Validation Reveal the Potential Antidepressant-Like Effects of Chaihu Shugan San Associated With Glutamate Homeostasis.Food science & nutrition · 2026Article
- Dietary Phytonutrients in Fibromyalgia: Integrating Mechanisms, Biomarkers, and Clinical Evidence-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Depression and pain are frequently comorbid and interact to produce a more difficult clinical picture and decreased response to therapy. Isorhamnetin, a naturally occurring flavonoid, has been suggested to exert an impact on oxidative stress, inflammation, and neurotransmitter pathways related to both disorders. The objective of this work was to investigate the neuroprotective, antidepressant, and antinociceptive effects of isorhamnetin in reserpine-treated mice, which represent a model of pain-depression dyad. Three days of consecutive reserpine (0.5 mg/kg; s.c.) injection was used to establish the depression and pain model in adult male mice. Isorhamnetin (50 mg/kg) or gabapentin (10 mg/kg) was given orally 30 min before reserpine. Behavioral analyses, including electronic von Frey test (eVF) pressure application measurement (PAMF), forced swim test (FST), and Morris water maze (MWM), were performed. Biochemical analysis involved levels of oxidative stress markers (GSH, TBARS), the activity of monoamine oxidase-A (MAO-A) enzyme, proinflammatory cytokines (TNF-α, IL-1β), and brain aromatics levels (5-HT, NE, glutamate). Isorhamnetin restored the paw withdrawal thresholds to approximately those measured in the control group and decreased immobility times (p < 0.01). In the MWM, isorhamnetin significantly shortened the latency to find the platform (p < 0.001), implying good spatial memory. Biochemical assessments showed that isorhamnetin significantly reduced oxidative burden, as evidenced by elevated GSH concentrations (p < 0.001) and decreased TBERS levels (p < 0.05), while suppressing MAO-A activity (p < 0.05). It also decreased serum levels of TNF-α and IL-1β (p < 0.01) and normalized levels of neurotransmitters, with decreased glutamate and increased serotonin and norepinephrine (p < 0.05). Isorhamnetin exhibited marked antidepressant, antinociceptive, and cognitive-improving activities possibly mediated via antioxidant, anti-inflammatory, and monoaminergic modulatory actions. These observations emphasize the therapeutic promise for treating the complex clinical coexistence of chronic pain and depression.
Indexed as
Identifiers
40707861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.